NewsRx

Search our medical news database

Overactive Bladder

Data: Once-daily solifenacin succinate improves key symptoms of OAB in women

Published in Women's Health Weekly, June 3rd, 2004

Solifenacin succinate, a once-daily oral antimuscarinic agent in development, significantly reduced the three key symptoms of overactive bladder (OAB) - urgency, frequency, and incontinence - in four pooled trials involving 2466 women, according to data presented at the annual meeting of the American College of Obstetrics and Gynecology.

Solifenacin appears to be the first antimuscarinic agent to report consistent and statistically significant reductions in the three main symptoms of OAB across multiple trials in both men and women. OAB is a condition that affects approximately 17% of women 40 years of age or older.

The data showed that 63% of women...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook